The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions

Gennaro Chiappetta; Paolo Toti; Francesco Cetta; Ada Giuliano; Francesca Pentimalli; Ida Amendola; Stefano Lazzi; Mario Monaco; Luca Mazzuchelli; Piero Tosi; Massimo Santoro; Alfredo Fusco

doi:10.1210/jc.87.1.364

The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions

Gennaro Chiappetta, Paolo Toti, Francesco Cetta, Ada Giuliano, Francesca Pentimalli, Ida Amendola, Stefano Lazzi, Mario Monaco, Luca Mazzuchelli, Piero Tosi, Massimo Santoro, Alfredo Fusco

Research output: Contribution to journal › Article › peer-review

Abstract

Hurthle cell adenomas and carcinomas, characterized by the presence of oncocytic cells, are unusual thyroid neoplasms, the treatment of which is still controversial. We analyzed specimens from 49 patients with oncocytic cell nodular lesions including 20 adenomas, 19 carcinomas, and 10 hyperplasias for RET/PTC (papillary thyroid carcinoma) activation, which is the most frequent genetic alteration in PTCs. RET/PTC activation was detected in a significant number of cases of Hurthle cell adenomas and carcinomas, but in 0 of 10 patients with hyperplastic nodules. In particular, the RET/PTC1 isoform was found in 7 of 12 adenomas and 4 of 7 carcinomas. These results would indicate that RET/PTC is a genetic event common to papillary carcinomas and to Hurthle cell neoplasias.

Original language	English
Pages (from-to)	364-369
Number of pages	6
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	87
Issue number	1
DOIs	https://doi.org/10.1210/jc.87.1.364
Publication status	Published - 2002

ASJC Scopus subject areas

Biochemistry
Endocrinology, Diabetes and Metabolism

Access to Document

10.1210/jc.87.1.364

Cite this

Chiappetta, G., Toti, P., Cetta, F., Giuliano, A., Pentimalli, F., Amendola, I., Lazzi, S., Monaco, M., Mazzuchelli, L., Tosi, P., Santoro, M., & Fusco, A. (2002). The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. Journal of Clinical Endocrinology and Metabolism, 87(1), 364-369. https://doi.org/10.1210/jc.87.1.364

The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. / Chiappetta, Gennaro; Toti, Paolo; Cetta, Francesco et al.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 1, 2002, p. 364-369.

Research output: Contribution to journal › Article › peer-review

Chiappetta, G, Toti, P, Cetta, F, Giuliano, A, Pentimalli, F, Amendola, I, Lazzi, S, Monaco, M, Mazzuchelli, L, Tosi, P, Santoro, M & Fusco, A 2002, 'The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions', Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 1, pp. 364-369. https://doi.org/10.1210/jc.87.1.364

@article{75b6a7e41b324efb83f69b56e0aa5052,

title = "The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions",

abstract = "Hurthle cell adenomas and carcinomas, characterized by the presence of oncocytic cells, are unusual thyroid neoplasms, the treatment of which is still controversial. We analyzed specimens from 49 patients with oncocytic cell nodular lesions including 20 adenomas, 19 carcinomas, and 10 hyperplasias for RET/PTC (papillary thyroid carcinoma) activation, which is the most frequent genetic alteration in PTCs. RET/PTC activation was detected in a significant number of cases of Hurthle cell adenomas and carcinomas, but in 0 of 10 patients with hyperplastic nodules. In particular, the RET/PTC1 isoform was found in 7 of 12 adenomas and 4 of 7 carcinomas. These results would indicate that RET/PTC is a genetic event common to papillary carcinomas and to Hurthle cell neoplasias.",

author = "Gennaro Chiappetta and Paolo Toti and Francesco Cetta and Ada Giuliano and Francesca Pentimalli and Ida Amendola and Stefano Lazzi and Mario Monaco and Luca Mazzuchelli and Piero Tosi and Massimo Santoro and Alfredo Fusco",

year = "2002",

doi = "10.1210/jc.87.1.364",

language = "English",

volume = "87",

pages = "364--369",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "1",

}

TY - JOUR

T1 - The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions

AU - Chiappetta, Gennaro

AU - Toti, Paolo

AU - Cetta, Francesco

AU - Giuliano, Ada

AU - Pentimalli, Francesca

AU - Amendola, Ida

AU - Lazzi, Stefano

AU - Monaco, Mario

AU - Mazzuchelli, Luca

AU - Tosi, Piero

AU - Santoro, Massimo

AU - Fusco, Alfredo

PY - 2002

Y1 - 2002

N2 - Hurthle cell adenomas and carcinomas, characterized by the presence of oncocytic cells, are unusual thyroid neoplasms, the treatment of which is still controversial. We analyzed specimens from 49 patients with oncocytic cell nodular lesions including 20 adenomas, 19 carcinomas, and 10 hyperplasias for RET/PTC (papillary thyroid carcinoma) activation, which is the most frequent genetic alteration in PTCs. RET/PTC activation was detected in a significant number of cases of Hurthle cell adenomas and carcinomas, but in 0 of 10 patients with hyperplastic nodules. In particular, the RET/PTC1 isoform was found in 7 of 12 adenomas and 4 of 7 carcinomas. These results would indicate that RET/PTC is a genetic event common to papillary carcinomas and to Hurthle cell neoplasias.

AB - Hurthle cell adenomas and carcinomas, characterized by the presence of oncocytic cells, are unusual thyroid neoplasms, the treatment of which is still controversial. We analyzed specimens from 49 patients with oncocytic cell nodular lesions including 20 adenomas, 19 carcinomas, and 10 hyperplasias for RET/PTC (papillary thyroid carcinoma) activation, which is the most frequent genetic alteration in PTCs. RET/PTC activation was detected in a significant number of cases of Hurthle cell adenomas and carcinomas, but in 0 of 10 patients with hyperplastic nodules. In particular, the RET/PTC1 isoform was found in 7 of 12 adenomas and 4 of 7 carcinomas. These results would indicate that RET/PTC is a genetic event common to papillary carcinomas and to Hurthle cell neoplasias.

UR - http://www.scopus.com/inward/record.url?scp=0036149992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036149992&partnerID=8YFLogxK

U2 - 10.1210/jc.87.1.364

DO - 10.1210/jc.87.1.364

M3 - Article

C2 - 11788677

AN - SCOPUS:0036149992

VL - 87

SP - 364

EP - 369

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -

The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this